CARsgen Therapeutics (HKG:2171) said it expects to book narrower losses in 2025, according to a Hong Kong bourse filing Monday.
The firm expects a net loss of up to 120 million yuan for the year, compared with the 798 million yuan loss posted a year earlier.
The company's financial results are due in early March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.